AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05104125
Drug: ASC40 75mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75mg of ASC40 orally once daily for 12 weeks.
Trial: NCT05104125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally once daily for 12 weeks.
Trial: NCT04112199
Drug: BIV201 continuous infusion
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIV201 continuous infusion with terlipressin for a total of two 28 day cycles. Initiate treatment at 3 mg per 24 hour period and titrate stepwise up to a maximum of 8 mg per 24 hour period based on tolerability and response.
Trial: NCT04964375
Drug: ABSK043 oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABSK043 is a novel, oral small molecule inhibitor of PD-L1
Trial: NCT06358963
Drug: Non-Medicare Drugs
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: and Group C did not receive any medication; after the two-month study period, the clinical periodontal parameters were reassessed. Additionally, to compare teh total antioxidant capacity in saliva before and after teh intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at teh beginning and end of teh study for analysis using UV-spectrophotometric methods, furthermore, teh following criteria determined teh selection of eligible participants for dis study.
Trial: NCT04876924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BBP-711
Trial: NCT05104229
Drug: Aspirin 81Mg Ec Tab
RxNorm normalized name: ASPIRIN 81MG EC TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 81Mg Ec Tab by mouth twice daily starting the day after surgery until hospital discharge, then for 30 days
Trial: NCT05104229
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care VTE prophylaxis
Trial: NCT05281471
Drug: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered according to local practice
Trial: NCT05434091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be prepared as an oral solution and/or suspension given in each cohort
Trial: NCT05717374
Drug: caudal block using methylprednisolone
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive 0.5 ml/kg volume (bupivacaine 0.25% + methylprednisolone 0.5mg/kg) through the sacral hiatus
Trial: NCT04080895
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
Trial: NCT05428150
Drug: Esbriet 267 MG Oral Capsule
RxNorm normalized name: Esbriet 267 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference Formulation
Trial: NCT05959486
Drug: BR6002A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone
Trial: NCT05959486
Drug: BR6002B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone
Trial: NCT05959486
Drug: BR6002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule administered alone
Trial: NCT05740748
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo sc q4wks for 20 weeks
Trial: NCT05524155
Drug: HAIC
RxNorm normalized name: Hepatic Arterial Infusion Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
Trial: NCT05292040
Drug: LY3857210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05650216
Drug: Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2)，Immunotherapy (camrelizumab 200mg)、Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy， distant lymph node 0.5Gy*4)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Neoadjuvant treatment period:~   Radiotherapy: Primary lesions and adjacent lymph nodes: The mode of involved field irradiation (IFI) is adopted, no preventive radiation is given. The total dose is 41.4Gy, 1.8Gy/23f. Distal lymph nodes ≥ 5cm away from the primary lesion: low-dose radiotherapy with a total dose of 4Gy, 0.5Gy/8f, Day1 to Day4, Day22 to Day25.~   Chemotherapy: Carboplatin(AUC=2), Nab-paclitaxel(80mg/m2), Day1/8/15/22/29. Immunotherapy: Camrelizumab(200mg, Day5, Day26).~2. Perioperative period:~   Undergo surgery within 4-6 weeks after neoadjuvant therapy~3. Adjuvant treatment period:~Camrelizumab: (200mg, Q3W)，continued for up to 1 years，until PD or intolerable toxicity.
Trial: NCT06207253
Drug: Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
Trial: NCT06207253
Drug: Calcium hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
Trial: NCT06408532
Drug: IDegLira
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants in this group will be switched to IDegLira once daily injection therapy.
Trial: NCT05057572
Drug: Standard Medical Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Arm B will receive standard medical therapy.SMT (as described) that is Grade II ascites - Lasilactone (20/50) OD then Change after 1 week as per response, monitor diuretic intolerance.~* Grade III ascites will undergo large volume paracentesis, lasilactone (20/50) OD Both groups will receive albumin as indicated (LT references as per protocol will be send for eligible patients)
Trial: NCT06449703
Drug: Xultophy®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xultophy®
Trial: NCT04183595
Drug: (N1, N3-bis(2- mercaptoethyl)isophthalamide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mg / day NBMI treatment for 14 days, administered as four capsules of 100 mg of NBMI every 24 hours, at the start of treatment, the principal investigator or his delegate will verify the intake of the first dose and deliver a blister pack corresponding to the remaining NBMI capsules, at visit day 14 research subjects will be asked to return the packaging with the remaining capsules or not, in order to estimate adherence to treatment.
Trial: NCT05642910
Drug: Paxlovid group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received Paxlovid orally for 5 consecutive days (10 doses in total).
Trial: NCT05193734
Drug: Pertagen®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule:~Group Pertagen will receive two doses of Pertagen®. (one vaccination on Day 0 and 6 months later for each volunteer.)~Mode of Administration:~Intramuscular injection into the deltoid region of the upper extremity, using a syringe with a 1 to 1.5 inch #25-gauge sterile needle.
Trial: NCT05193734
Drug: Revaxis®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule:~Group Control will receive one dose of Revaxis® on Day 0 followed by 1 dose of Pertagen® 6 months later for each volunteer.~Mode of Administration:~Intramuscular injection into the deltoid region of the upper extremity, using a syringe with a 1 to 1.5 inch #25-gauge sterile needle.
Trial: NCT04842435
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In a Stage 1 study, Placebo is administered to clinical study subjects randomized to groups 4 by intravenous drip at a dose of 1 mL/kg.~The initial drug administration rate is from 0.01 mL/kg to 0.02 mL/kg of body weight per minute for 30 minutes. If the drug is well tolerated, the rate of administration can be gradually increased to a maximum of 0.12 mL/kg of body weight per minute. In order to control the drug administration rate, infusion shall be performed with an infusion pump.~In a Stage 2 study, placebo is administered to clinical study subjects randomized to group 2 by intravenous drip at a dose equal to the study drug dose.
Trial: NCT06603766
Drug: IV Magnesium Sulfate
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MgSO₄'s mechanism in PPHN includes activating cellular processes, modulating membrane excitability, and acting as a physiological calcium antagonist. It exerts sedative, muscle relaxant, and bronchodilatory properties, while concurrently inducing a state of alkalosis.
Trial: NCT06603766
Drug: Inhalational magnesium sulfate
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It gives us the same mechanism of action as IV MgSO4 with less side effects.
Trial: NCT01504282
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: balanced salt solution (BSS)
Trial: NCT05663255
Drug: Discontinuation of respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation or reduction of at least one respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics)
Trial: NCT05181995
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 50 mg NYX-783
Trial: NCT05450549
Drug: DNL919
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses
Trial: NCT05450549
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses
Trial: NCT06473909
Drug: CD25 antibody combined glucocorticoid as first-line treatment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CD25 antibody combined glucocorticoid as first-line treatment
Trial: NCT04813445
Drug: Xingnaojing injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
Trial: NCT05198505
Drug: TQB2868 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2868 protein is a bi-functional fusion protein targeting PD-1 and TGF-β
Trial: NCT06597682
Drug: Vitamin C combined with Coenzyme Q10 oral treatment
RxNorm normalized name: vitamin C combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total 4 weeks of treatment
Trial: NCT06444594
Drug: TRPV1 Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: camphor gel 5-20%
Trial: NCT06444594
Drug: TRPM8, TRPV4, TRPV1 Agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: menthol (4-10%), capsaicin (0.05-1%), camphor (5-20%)
Trial: NCT06597422
Drug: STSP-0902 ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drop, single dose
Trial: NCT06597422
Drug: STSP-0902 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drop, single dose
Trial: NCT05808972
Drug: Ringer lactate (RL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention will continue for 48 hours from admission to the ICU with a blood gas control (including base excess) + Blood glucose + ionogram (Na, K, chlorine) + lactates on admission (or H0), H6, H12, H24 and H48.
Trial: NCT06597422
Drug: STSP-0902 ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drop, three times daily for a total of 8 days
Trial: NCT06597422
Drug: STSP-0902 ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drop, six times daily for a total of 8 days
Trial: NCT06597422
Drug: STSP-0902 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drop, multiple doses
Trial: NCT06597422
Drug: STSP-0902 ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drop, single dose, tear samples will be collected
Trial: NCT05841693
Drug: Carbohydrate
RxNorm normalized name: CARBOHYDRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental group of patients will consume the carbohydrate rich fluid 2 hours before the elective CD.
Trial: NCT06315387
Drug: 4-MUST, 1 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-methylumbelliferyl trimebutine sulfate, 128 mg
Trial: NCT06315387
Drug: 4-MUST, 2 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-methylumbelliferyl trimebutine sulfate, 256 mg
Trial: NCT06315387
Drug: 4-MUST, 3 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-methylumbelliferyl trimebutine sulfate, 384 mg
Trial: NCT04659096
Drug: ION537
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ION537 will be administered by IV injection.
Trial: NCT05422703
Drug: Proteolytic enzymes
RxNorm normalized name: Proteolytic enzymes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-2 ampoules daily IM box of 3 ampoules of 5 mg crystallized and lyophilized chymotrypsin (450 E. A. Units) + 3 ampoules of 3 ml apyrogenic saline for one week.
Trial: NCT04766398
Drug: KHK7791
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT04766398
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT05830747
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-operative Placebo administration before third molar surgery
Trial: NCT05462717
Drug: RMC-6291
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet once or twice a day
Trial: NCT01412359
Drug: Omegaven®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omegaven® 10% fat emulsion 1g/kg/day to infuse via IV over a period of 12 -24 hours every day until patient no longer requires intravenous lipid emulsion, is determined ineffective, or the patient stops participating in the study for any reason.
Trial: NCT04857333
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For pulmonary nodules with features of infectious disease, antibiotics is recommended
Trial: NCT02963350
Drug: BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05178524
Drug: BIFICO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live combined Bifidobacterium, Lactobacillus and Enterococcus Capsules
Trial: NCT06503224
Drug: Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenous infusion of anti-BCMA and CD19 CART cells (dose-escalating infusion of 0.5-3 x10\^6 CART cells/kg）.
Trial: NCT06463327
Drug: TCB008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCB008 is derived from the peripheral blood mononuclear cells (PBMCs) of unrelated, healthy donors and consists of expanded cluster designation (CD)3+ T cells expressing the γ chain variable region 9 δ-chain variable region 2 (Vγ9Vδ2) T cell receptor (TCR); it is infused into patients to boost their immune system. It is currently developed for treatment of cancers and infectious diseases.
Trial: NCT06599528
Drug: T-R (Test-Reference drug)
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T: SJ04 (Test drug) R: Ovidrel® (Referecne drug) 250 μg of SJ04 injection or Oviderl®, administered subcutaneously once at two week intervals.
Trial: NCT06599528
Drug: R-T (Reference-Test drug)
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R: Ovidrel®(Referecne drug) T: SJ04 (Test drug) 250 μg of SJ04 or Oviderl®, administered subcutaneously once at two week intervals.
Trial: NCT06602466
Drug: Test toothpaste
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.454% Stannous Fluoride, 0.3% Zinc Chloride,1% Alumina toothpaste containing 1100 parts per million (ppm) fluoride.
Trial: NCT05883956
Drug: Oral decitabine/cedazuridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral decitabine 35mg/cedazuridine 100mg, once daily, 5 days
Trial: NCT06403150
Drug: Fosphenytoin Injection
RxNorm normalized name: fosphenytoin Injection
DrugBank: Fosphenytoin (DB01320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosphenytoin at 20 mg/kg (Phenytoin equivalent dose of 15 mg/kg) will be intravenously administered in 100mL of normal saline at an administration rate not exceeding 3mg/kg/min or 150 mg/min. After 30 minutes following the Fosphenytoin needle time reassessment of the patient will be done to determine the outcomes.
Trial: NCT06036589
Drug: CA and BAM8-22
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA (tran-cinnamaldheyde) solution (in ethanol 5%) application and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
Trial: NCT06036589
Drug: Vehicle and BAM8-22 application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (ethanol) application and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
Trial: NCT06036589
Drug: vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (ethanol) application and inactivate cowhage spicules will be applied to a previously determined area on the volar forearm
Trial: NCT06593600
Drug: REGN7544
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) administration
Trial: NCT06593600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC administration
Trial: NCT04991584
Drug: Amoxicillin,Tetracycline,Furazolidone,Levofloxacin,Vonoprazan fumarate, Esomeprazole ,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment.
Trial: NCT05150405
Drug: QLF31907
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this study, seven dose groups were proposed. The frequency of administration was once every two weeks, and four weeks was one therapeutic cycle. The subjects will receive six cycles of QLF31907 treatment at most.
Trial: NCT05263505
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Target dose: 20mg weekly
Trial: NCT05263505
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Target dose: 2mg/kg daily
Trial: NCT05692154
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine matching placebo oral tablet
Trial: NCT06293807
Drug: Xylocaine 2 % with 1:100,000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic used during dental procedures
Trial: NCT06293807
Drug: Bupivicaine 0.5% with 1:200,000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic used during dental procedures
Trial: NCT05654753
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 20 capsules placebo, each containing placebo at once at day 0, then 3 capsules/day from day 1 through day 20.
Trial: NCT05065619
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
Trial: NCT05160220
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g dried edible non-psychoactive mushroom material.
Trial: NCT04976023
Drug: Yupingfeng Powder granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14.5 5 g twice daily for 8 weeks
Trial: NCT05629325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks of treatment with placebo
Trial: NCT05141305
Drug: standard medical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone are being used.
Trial: NCT04959032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching capsules administered orally, once daily.
Trial: NCT05684380
Drug: MAZ-101association
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental drug
Trial: NCT05684380
Drug: DYMISTA®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator
Trial: NCT06768944
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactive placebo
Trial: NCT06248645
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow medical air (12 L/min) administered with a non-rebreathing facial mask, started as soon as possible after the beginning of the attack and for 15 minutes.
Trial: NCT06152978
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (75mg/m2) wih routine hydration for 3 days and nab-paclitaxel (260mg/m2) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.
Trial: NCT00031057
Drug: Thiamine hydrochloride
RxNorm normalized name: Thiamine Hydrochloride
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05841394
Drug: Placebo 1
RxNorm normalized name: placebo 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic saline for injection, 100 ml/bag, q24h, following Ilaprazole Sodium with a time interval of 12 h.
Trial: NCT05841394
Drug: Placebo 2
RxNorm normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic saline for injection, 100 ml/bag, q12h, dosing on the first day.
Trial: NCT06768840
Drug: oral mini pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pulse dose of oral dexamethasone 2.5mg for adults for two consecutive days per week and half the dose for children
Trial: NCT05076682
Drug: Choline
RxNorm normalized name: Choline
DrugBank: Choline (DB00122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Choline 300mg tid or 500mg bid, p.o